Asset Details
Do you wish to reserve the book?
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
Do you wish to request the book?
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
2015
Overview
In the face of diminishing therapeutic options for the treatment of infections caused by multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and polymyxin B. These antibiotics became available clinically in the 1950s, when understanding of antimicrobial pharmacology and regulatory requirements for approval of drugs was substantially less than today. At the 1st International Conference on Polymyxins in Prato, Italy, 2013, participants discussed a set of key objectives that were developed to explore the factors affecting the safe and effective use of polymyxins, identify the gaps in knowledge, and set priorities for future research. Participants identified several factors that affect the optimum use of polymyxins, including: confusion caused by several different conventions used to describe doses of colistin; an absence of appropriate pharmacopoeial standards for polymyxins; outdated and diverse product information; and uncertainties about susceptibility testing and breakpoints. High-priority areas for research included: better definition of the effectiveness of polymyxin-based combination therapy compared with monotherapy via well designed, randomised controlled trials; examination of the relative merits of colistin versus polymyxin B for various types of infection; investigation of pharmacokinetics in special patient populations; and definition of the role of nebulised polymyxins alone or in combination with intravenous polymyxins for the treatment of pneumonia. The key areas identified provide a roadmap for action regarding the continued use of polymyxins, and are intended to help with the effective and safe use of these important, last-line antibiotics.
Publisher
Elsevier Ltd,Elsevier Limited,New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001
Subject
Anti-Bacterial Agents - administration & dosage
/ Anti-Bacterial Agents - adverse effects
/ Anti-Bacterial Agents - pharmacology
/ Anti-Bacterial Agents - therapeutic use
/ Bacteria
/ Colistin - administration & dosage
/ Gram-Negative Bacterial Infections - drug therapy
/ Humans
/ Italy
/ Microbial Sensitivity Tests - standards
/ Polymyxin B - administration & dosage
/ Polymyxin B - adverse effects
/ Polymyxin B - therapeutic use
/ Studies
